Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)


BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase 7,650 shares of its common stock under the Company’s 2023 Inducement Plan.

See more here:
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Related Posts